Kyongbo Pharmaceutical Co., Ltd (KRX:214390)
South Korea flag South Korea · Delayed Price · Currency is KRW
6,320.00
+310.00 (5.16%)
At close: Oct 2, 2025

Kyongbo Pharmaceutical Revenue

Kyongbo Pharmaceutical had revenue of 65.31B KRW in the quarter ending June 30, 2025, with 11.81% growth. This brings the company's revenue in the last twelve months to 243.45B, up 2.78% year-over-year. In the year 2024, Kyongbo Pharmaceutical had annual revenue of 238.56B with 10.26% growth.

Revenue (ttm)
243.45B
Revenue Growth
+2.78%
P/S Ratio
0.62
Revenue / Employee
n/a
Employees
n/a
Market Cap
151.33B

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 2024238.56B22.20B10.26%
Dec 31, 2023216.36B20.09B10.24%
Dec 31, 2022196.26B25.61B15.00%
Dec 31, 2021170.66B-44.63B-20.73%
Dec 31, 2020215.29B23.58B12.30%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company NameRevenue
Samsung Biologics5,031.69B
Celltrion3,748.95B
ALTEOGEN158.06B
Yuhan2,165.44B
SK Biopharmaceuticals620.28B
Peptron5.18B
PharmaResearch449.81B
LigaChem Biosciences148.28B
Revenue Rankings